source
- Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s JournavxLatigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.Fierce Biotech · 12h ago↗ source
- California Supreme Court rejects claim that Gilead must fast-track safer HIV drugThousands of patients sued Gilead Sciences, alleging the company was negligent for delaying a safer HIV medicine and that they suffered kidney injury and bone loss from the older drug. The Califor…